Venture Capital: Convergent Therapeutics Lands $90M For Treatment Of Cancers Using Radiopharmaceuticals

May 4, 2023 | News, Venture Capital

The Convergent lead program focuses on treatment of advanced prostate cancer.

Convergent Therapeutics Inc., a clinical-stage biotech firm specializing in developing next-generation radiopharmaceuticals for cancer treatment, has completed a $90 million Series A financing led by OrbiMed and RA Capital Management, with Invus participating.

The funds will aid in the development of a pipeline of novel radioantibodies, including its lead program, CONV01-α, for treating advanced prostate cancer. Convergent’s co-founders are Dr. Philip Kantoff, former Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center, and Dr. Neil Bander, a urologic oncology professor at Weill Cornell Medicine, who were also the first to validate PSMA as a cancer target. (CISION PR NEWSWIRE)

CONV01-α is viewed as a best-in-class, targeted treatment for prostate cancer, and Convergent Therapeutics intends to advance its clinical development soon. The company intends to pursue additional radioantibody targets for cancer treatment while also evaluating in-licensing and pipeline acquisition opportunities.

The radioantibody approach of the company is ideally suited to treat cancer and develop effective treatments, said Tal Zaks, M.D., Ph.D., Partner at OrbiMed.

The radioantibody technology of Convergent Therapeutics is an exciting approach to radiopharmaceuticals, according to Jake Simson, Ph.D., Partner at RA Capital Management, who also added that Convergent is well-positioned.

Related Story: The FDA Clears ProstatID, An AI That Helps Detect Prostate Cancer From MRIs

Photo by National Cancer Institute on Unsplash

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
Artificial Intelligence: AMD Takes On Rivals In The AI Chip Sweepstakes
December 7, 2023     Artificial Intelligence, News

Chipmaker AMD (NASDAQ: AMD) has unveiled a range of innovative AI solutions spanning from data centers to personal computers. The AMD Instinct MI300 Series features data center AI accelerators, while…
Digital Assets: Robinhood Debuts Crypto Trading On Its App In The EU
December 7, 2023     Digital Assets, FinTech, News

Robinhood (NASDAQ: HOOD) has launched its Crypto app in the European Union (EU), allowing eligible customers to engage in crypto trading with the added incentive of earning Bitcoin rewards. Customers…
FinTech: Samsung Electronics Ties With Mastercard’s Wallet Express
December 7, 2023     FinTech, News

Samsung Electronics (KRX: 005930) and Mastercard (NYSE: MA) have partnered to launch the Wallet Express program, offering banks and card issuers a cost-effective way to expand digital wallet offerings. Through…
Venture Capital: Revaia, Europe’s Biggest Female-Led VC Firm, Racks Up $160M For Second Fund
December 7, 2023     ESG and Sustainability, News, Venture Capital

Revaia, Europe’s largest female-founded venture capital firm, has successfully raised €150 million ($160 million) for its second fund, Revaia Growth II. The funding was secured from sovereign wealth funds, family…